Paper2142014
Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
Garrido MA and 7 others. Cancer Res, 1990. Cited by 59 papers, by iCite.
Cite this record
ConductScience Library. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice. Papers, record 2142014. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2142014
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Ovarian Neoplasms | Major topic |
| T-Lymphocytes | Major topic |
| Animals | |
| Antigens, Differentiation, T-Lymphocyte | |
| CD3 Complex | |
| Cell Line | |
| Cell Survival | |
| Cells, Cultured | |
| Female | |
| Humans | |
| Immunotherapy | |
| Interleukin-2 | |
| Mice | |
| Mice, Nude | |
| Neoplasm Transplantation | |
| Receptors, Antigen, T-Cell | |
| Recombinant Proteins | |
| Transplantation, Heterologous |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 59 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 20694021 | Research and development of next generation of antibody-based therapeutics. | Acta Pharmacol Sin | 2010 | https://conductscience.org/library/papers/20694021 | PubMed |
| 8908701 | Targeting of peripheral blood T lymphocytes. | Springer Semin Immunopathol | 1996 | https://conductscience.org/library/papers/8908701 | PubMed |
| 8795576 | Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. | Br J Cancer | 1996 | https://conductscience.org/library/papers/8795576 | PubMed |
| 7728777 | Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo. | Cancer Immunol Immunother | 1995 | https://conductscience.org/library/papers/7728777 | PubMed |
| 2242603 | Strategies in antibody therapy of cancer. | Clin Exp Immunol | 1990 | https://conductscience.org/library/papers/2242603 | PubMed |
| 1386300 | Bispecific anti-human red blood Rhesus-D antigen x anti Fc gamma RI targeted antibody-dependent cell-mediated cytotoxicity and phagocytosis by mononuclear leucocytes. | Clin Exp Immunol | 1992 | https://conductscience.org/library/papers/1386300 | PubMed |
| 1346155 | Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. | J Exp Med | 1992 | https://conductscience.org/library/papers/1346155 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2142014
GET https://conductscience.org/api/papers/v1/2142014/authors